Skip to main content
BIO·ATLASby Bayes Pharma.ai
Search
AccountStart evaluation
AI drug discovery models/AI-Native Discovery Cos./Xaira Therapeutics
organization passport · Review date not recorded

Xaira Therapeutics

A $1B+ launch fusing Baker-lab design with drug development.

1/7Evidence fields documented
60-SECOND EVALUATION VIEW

What should a scientist know before using Xaira Therapeutics?

UnresolvedEvidence direction is incomplete or not yet resolved
Best suited forPlatform · Discovery
Evidence supportsPrimary links may be present, but BioAtlas does not claim a review date without a record-level timestamp.
Evidence does not establishUniversal superiority, therapeutic success, clinical utility or regulatory acceptance.
Major limitationIndependent reproducibility is limited by proprietary access.
CompareAdd to evaluationView evidence
Current registry recordVersion history pending0 recorded releases · Review date not recorded. A newer version is not assumed to be universally better.

What it is

Xaira launched in 2024 with over $1B in committed capital (from ARCH and Foresite) to build an AI-first drug company spanning generative molecular design and large-scale functional-genomics data. It draws on David Baker's protein-design breakthroughs (RFdiffusion lineage) and aims to run the full loop from target biology to clinical candidates.

Evidence trail

BioAtlas keeps the path from source to decision visible. A connection records provenance; it does not imply that evidence is sufficient for every context.

Sources1 connectedPrimary resources and normalized claims
Claims0 normalizedNo normalized claim yet
EntityXaira Therapeuticsorganization · Version history pending
ReviewReview date not recordedReview date not claimed
ConclusionContext requiredAdd to an evaluation before operational use

Model passport

Entity typeorganization
OrganizationXaira Therapeutics
Organization founded2024
AccessProprietary
Commercial useVendor terms
DeploymentVendor managed
ComputeVendor managed
Domainscompany
Biology → representation → computation → evidence

How Xaira Therapeutics represents biology

organizationcompany

Category is navigation. These fields describe the model-specific computational transformation and deliberately override broad category defaults.

1 · Biological inputs
Disease hypothesis and multimodal evidence
2 · Input representation
Organization / platform dependent
3 · Internal representation
Multiple systems
4 · Architecture
Organization / discovery system
5 · Learning objective
Integrated discovery
6 · Output representation
Programs and evidence

Biological scale

Modalities & tasks

MultimodalPlatformDiscovery

Registry, claims and frontier intelligence

Versioned registry

Version history pending

0 version records · release year not yet normalized. Model-family identity remains separate from capability and access changes.

Explore version lineage →
Benchmark claim ledger

0 normalized claims

No task, dataset, split and metric claim has been normalized for this record yet.

Open claim intelligence →

Inputs and outputs

Inputs

Disease hypothesis and multimodal evidence

Outputs

Targets, candidates or development programs

Scientific and technical profile

Scientific principles

Generative protein/molecule designFunctional genomics at scaleFull-stack discovery

Technology

Diffusion protein designPerturbation/omics data enginesIntegrated wet lab
Ideas before algorithms

Scientific lineage

Explore all foundations

These are transparent concept matches—not claims that one scientist alone caused this model. Each connection is based on the model’s recorded domain, scientific principles, technical terms or an explicit lineage link.

Medicinal chemistry & pharmacology

Selective toxicity and the ‘magic bullet’

Paul Ehrlich

Target selectivity, therapeutic index and mechanism-based screening remain central goals of drug discovery.

Matched concepts: target, therapeutic
Medicinal chemistry & pharmacology

Rational antimetabolite drug design

Gertrude B. Elion & George H. Hitchings

Mechanism-based design, pathway selectivity and iterative medicinal chemistry are direct descendants of this strategy.

Matched concepts: candidate
Genomics & cell systems

Gene regulation and the operon model

François Jacob & Jacques Monod

Target biology, perturbation models, transcriptomic response prediction and virtual cells all require an explicit model of regulated gene programs.

Matched concepts: perturbation
Medicinal chemistry & pharmacology

Quantitative structure–activity relationships

Corwin Hansch

Classical QSAR established the central premise that molecular features can predict potency and guide optimization—the conceptual ancestor of modern molecular machine learning.

Matched concepts: molecule
Biologics & genome engineering

Directed evolution of enzymes and proteins

Frances H. Arnold

Generative protein design increasingly closes the loop with directed evolution and experimental selection to optimize function and manufacturability.

Matched concepts: protein design
Biologics & genome engineering

Programmable CRISPR–Cas genome editing

Jennifer A. Doudna & Emmanuelle Charpentier

CRISPR enables target validation, disease models, perturbation atlases, functional genomics and gene-editing therapeutics.

Matched concepts: perturbation

Evaluation evidence

Dataset or evaluationNot yet curated
Task or metricNot yet extracted
Evidence statusNo task-specific benchmark record curated
Open source ↗

BioAtlas has not yet extracted a structured benchmark claim for this record.

Known limitations

  • Independent reproducibility is limited by proprietary access.
  • A structured benchmark claim has not yet been extracted for this record.
  • Outputs require task-specific scientific and experimental validation.

Milestones

2024

One of the largest biotech launches ever (>$1B).

Evidence

Ties to the Nobel-winning Baker lab.